ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating) CFO Dan Puckett sold 1,100 shares of the firm's stock in a transaction that occurred on Tuesday, December 20th. The stock was sold at an average price of $212.93, for a total value of $234,223.00. Following the transaction, the chief financial officer now owns 39,938 shares in the company, valued at $8,503,998.34. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Dan Puckett also recently made the following trade(s):
Get
ShockWave Medical alerts:
- On Monday, November 21st, Dan Puckett sold 1,100 shares of ShockWave Medical stock. The stock was sold at an average price of $246.96, for a total value of $271,656.00.
- On Thursday, October 20th, Dan Puckett sold 1,100 shares of ShockWave Medical stock. The stock was sold at an average price of $268.35, for a total value of $295,185.00.
ShockWave Medical Stock Down 2.6 %
Shares of NASDAQ:SWAV opened at $215.20 on Friday. The stock has a fifty day simple moving average of $253.56 and a two-hundred day simple moving average of $245.49. The stock has a market capitalization of $7.78 billion, a price-to-earnings ratio of 92.36 and a beta of 0.95. ShockWave Medical, Inc. has a 12-month low of $113.36 and a 12-month high of $320.54. The company has a current ratio of 7.29, a quick ratio of 6.02 and a debt-to-equity ratio of 0.04.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in ShockWave Medical by 2.0% during the third quarter. BlackRock Inc. now owns 4,400,318 shares of the company's stock valued at $1,223,596,000 after buying an additional 86,765 shares during the last quarter. Vanguard Group Inc. raised its stake in ShockWave Medical by 0.4% during the third quarter. Vanguard Group Inc. now owns 3,531,285 shares of the company's stock valued at $981,946,000 after buying an additional 13,619 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in ShockWave Medical by 24.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,214,678 shares of the company's stock valued at $614,550,000 after buying an additional 627,712 shares during the last quarter. Invesco Ltd. raised its stake in shares of ShockWave Medical by 16.0% in the first quarter. Invesco Ltd. now owns 1,398,211 shares of the company's stock worth $289,933,000 after purchasing an additional 192,525 shares during the last quarter. Finally, State Street Corp raised its stake in shares of ShockWave Medical by 2.8% in the third quarter. State Street Corp now owns 1,157,310 shares of the company's stock worth $321,813,000 after purchasing an additional 31,575 shares during the last quarter. Hedge funds and other institutional investors own 90.56% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on SWAV shares. Morgan Stanley lifted their price objective on ShockWave Medical from $255.00 to $290.00 and gave the stock an "equal weight" rating in a research report on Tuesday, October 11th. Oppenheimer lowered ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price objective on the stock. in a research report on Tuesday, September 6th. Deutsche Bank Aktiengesellschaft started coverage on ShockWave Medical in a research report on Friday, December 16th. They issued a "buy" rating and a $285.00 price objective on the stock. Wells Fargo & Company lowered ShockWave Medical from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $300.00 to $235.00 in a research report on Monday, December 12th. Finally, Bank of America lifted their price objective on ShockWave Medical from $260.00 to $310.00 in a research report on Monday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $258.22.
ShockWave Medical Company Profile
(Get Rating)
ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.
Further Reading
- Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- Are Caterpillar and Deere Setting Up to Rally in 2023?
- Mullen Automotive Gets a Jolt as the I-GO Arrives in Europe
- Will The Sun Shine On These 3 Large-Cap Solar Stocks In 2023?
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.
